Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Kool

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Translational Andrology and Urology|August 9, 2019
Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answersRonald Kool, José João Mansure, Wassim Kassouf
Human Pathology|May 1, 2022
Morphologic alterations post trimodal therapy in muscle-invasive urothelial carcinoma: understanding the impact of post-treatment changes on the pathological interpretation and their potential clinical correlatesGertruda Evaristo, Baharak Khadang, Ronald Kool, et al.
Therapeutic Advances in Urology|August 30, 2021
Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applicationsDenis Séguier, Philippe Puech, Ronald Kool, et al.
Jornal Vascular Brasileiro|June 23, 2018
Mário Vinícius Angelete Alvarez Bernardes, Ronald Kool, Ivan Neutzling Lüdtke, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 31, 2022
Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysisRonald Kool, Ivan Yanev, Tarek Hijal, et al.
Urologic Oncology|December 4, 2021
Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancerAhmad Almarzouq, Ronald Kool, Yarab Al Bulushi, et al.
European Urology Open Science|November 29, 2023
Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based TherapyCharles Hesswani, Chelsea L Jackson, Gautier Marcq, et al.
European Urology Open Science|November 10, 2022
Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based TherapyGautier Marcq, Gertruda Evaristo, Ronald Kool, et al.
International Journal of Radiation Oncology, Biology, Physics|October 24, 2025
The Clinical Relevance of Tertiary Lymphoid Structures in Assessing Treatment Response in Muscle-Invasive Bladder CancerNour Hassan, Eva Michaud, José Joao Mansure, et al.
Urologic Oncology|December 7, 2020
Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?Ronald Kool, Gautier Marcq, Adnan El-Achkar, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Translational Andrology and Urology|August 9, 2019
Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answersRonald Kool, José João Mansure, Wassim Kassouf
Human Pathology|May 1, 2022
Morphologic alterations post trimodal therapy in muscle-invasive urothelial carcinoma: understanding the impact of post-treatment changes on the pathological interpretation and their potential clinical correlatesGertruda Evaristo, Baharak Khadang, Ronald Kool, et al.
Therapeutic Advances in Urology|August 30, 2021
Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applicationsDenis Séguier, Philippe Puech, Ronald Kool, et al.
Jornal Vascular Brasileiro|June 23, 2018
Mário Vinícius Angelete Alvarez Bernardes, Ronald Kool, Ivan Neutzling Lüdtke, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 31, 2022
Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysisRonald Kool, Ivan Yanev, Tarek Hijal, et al.
Urologic Oncology|December 4, 2021
Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancerAhmad Almarzouq, Ronald Kool, Yarab Al Bulushi, et al.
European Urology Open Science|November 29, 2023
Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based TherapyCharles Hesswani, Chelsea L Jackson, Gautier Marcq, et al.
European Urology Open Science|November 10, 2022
Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based TherapyGautier Marcq, Gertruda Evaristo, Ronald Kool, et al.
International Journal of Radiation Oncology, Biology, Physics|October 24, 2025
The Clinical Relevance of Tertiary Lymphoid Structures in Assessing Treatment Response in Muscle-Invasive Bladder CancerNour Hassan, Eva Michaud, José Joao Mansure, et al.
Urologic Oncology|December 7, 2020
Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?Ronald Kool, Gautier Marcq, Adnan El-Achkar, et al.
Pageof 2